de Fost M - Search Results

1

Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial.

de Fost M, Aerts JM, Groener JE, Maas M, Akkerman EM, Wiersma MG, Hollak CE. de Fost M, et al. Haematologica. 2007 Feb;92(2):215-21. doi: 10.3324/haematol.10635. Haematologica. 2007. PMID: 17296571 Free article. Clinical Trial.

2

Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention.

Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, van Breemen MJ, van Meurs M, Boven LA, Laman JD, Moran MT, Cox TM, Aerts JM. Boot RG, et al. Among authors: de fost m. Blood. 2004 Jan 1;103(1):33-9. doi: 10.1182/blood-2003-05-1612. Epub 2003 Sep 11. Blood. 2004. PMID: 12969956 Free article.

3

Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis.

de Fost M, Hollak CE, Groener JE, Aerts JM, Maas M, Poll LW, Wiersma MG, Häussinger D, Brett S, Brill N, vom Dahl S. de Fost M, et al. Blood. 2006 Aug 1;108(3):830-5. doi: 10.1182/blood-2005-12-5072. Epub 2006 Mar 9. Blood. 2006. PMID: 16527890 Free article.

4

Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease.

van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, Maas M, Hollak CE, Aerts JM, Rezaee F. van Breemen MJ, et al. Among authors: de fost m. Biochim Biophys Acta. 2007 Jul;1772(7):788-96. doi: 10.1016/j.bbadis.2007.04.002. Epub 2007 Apr 14. Biochim Biophys Acta. 2007. PMID: 17499484 Free article.

5

Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy.

de Fost M, van Noesel CJ, Aerts JM, Maas M, Pöll RG, Hollak CE. de Fost M, et al. Haematologica. 2008 Jul;93(7):1119-20. doi: 10.3324/haematol.12651. Epub 2008 Jun 2. Haematologica. 2008. PMID: 18519519 Free article. No abstract available.

6

Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships.

Hollak CE, de Fost M, van Dussen L, Vom Dahl S, Aerts JM. Hollak CE, et al. Among authors: de fost m. Expert Opin Pharmacother. 2009 Nov;10(16):2641-52. doi: 10.1517/14656560903270520. Expert Opin Pharmacother. 2009. PMID: 19743939 Review.

7

Gaucher disease: from fundamental research to effective therapeutic interventions.

de Fost M, Aerts JM, Hollak CE. de Fost M, et al. Neth J Med. 2003 Jan;61(1):3-8. Neth J Med. 2003. PMID: 12688562 Free article. Review.

8

Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy.

Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE. Langeveld M, et al. Among authors: de fost m. Blood Cells Mol Dis. 2008 May-Jun;40(3):428-32. doi: 10.1016/j.bcmd.2007.09.002. Epub 2007 Oct 18. Blood Cells Mol Dis. 2008. PMID: 17950007

9

Low-dose versus high-dose therapy for Gaucher disease: Goals and markers.

Hollak CE, de Fost M, Aerts JM, vom Dahl S. Hollak CE, et al. Among authors: de fost m. Blood. 2007 Jan 1;109(1):387; author reply 387-8. doi: 10.1182/blood-2006-07-033233. Blood. 2007. PMID: 17190857 Free article. No abstract available.

10

Increased incidence of cancer in adult Gaucher disease in Western Europe.

de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Häussinger D, Hollak CE. de Fost M, et al. Blood Cells Mol Dis. 2006 Jan-Feb;36(1):53-8. doi: 10.1016/j.bcmd.2005.08.004. Epub 2005 Oct 24. Blood Cells Mol Dis. 2006. PMID: 16246599

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters